The proof is in the pie: ASA’s ruling against Beauty Pie for misleading claims

The ASA’s recent ruling against Beauty Pie is a useful warning for beauty brands, retailers and, really, any business marketing consumer products with bold efficacy claims, that the stronger and more definitive the promise is, the higher the evidential requirements are. 

The ad

Beauty Pie advertised its LED treatment mask with the headline claim that it was “clinically proven to reduce wrinkles in 4 weeks”. Smaller text referred to “results from a 4-week study of 28 people aged 30–65”. A complaint was made to the ASA, challenging whether that claim was misleading and adequately substantiated. 

What did the ASA rule? 

The ASA upheld the complaint on the basis that: 

• Consumer Interpretation: consumers would understand “clinically proven to reduce wrinkles in 4 weeks” to mean that the product had been scientifically proven to produce a visible wrinkle-reducing effect within that timeframe. The ASA also said that wording such as “skin tech that’s light years ahead” reinforced that impression
• The claim was a strong one, so the ASA expected strong evidence: The ASA said it expected “robust, product-specific evidence” to support the high claim of “clinically proven”.
• The main study was small: The study referred to in the ad involved 28 participants, which the ASA described as a “relatively small” sample size for substantiating a headline efficacy claim.
• The methodology had obvious weaknesses. The ASA identified the absence of a placebo or control group as a significant limitation to the study, and any claims coming out of it.
• Causation: Participants were also using skin cleansing pads and a hydrogel mask during testing study, so the ASA concluded that any reported improvements in the appearance of wrinkles could not clearly be attributed to the LED mask alone.
• “Equivalent technology” was not enough: Beauty Pie also relied on additional studies relating to similar LED technology, but the ASA found those studies were insufficient to substantiate the specific claim made for the advertised product. 

The key takeaway for brands

For in-house legal, regulatory and marketing teams, the key takeaways are: 

• Overclaiming in the headline. A punchy headline may be good for sales, but it also sets the compliance benchmark. If the headline suggests rigorous scientific proof, the evidence needs to justify that impression.
• Relying on imperfect studies. Small sample sizes, lack of controls, absence of blinding, or study conditions that do not reflect normal product use may all undermine substantiation.
• Trying to bridge evidential gaps with context or caveats. Small print is unlikely to rescue an overstated main claim if the overall impression remains too strong. The ASA’s focus is the message consumers are likely to take away.
• Using broader scientific material to support a product-specific claim. Evidence about ingredients, related technology or similar products may not be enough where the claim made is about the advertised product itself.
• Treat substantiation as a pre-publication issue, not a post-complaint scramble. Internal claims review between legal, regulatory and marketing teams is far cheaper than an upheld ASA ruling. This aligns with the broader compliance themes reflected in ASA/CAP training materials on misleading advertising and advertising governance.

This ruling is not just relevant when it comes to the use of tech in beauty industry, it is a broader advertising compliance point for any brand selling consumer products with performance, efficacy or science-led messaging. Under the CAP Code, marketers must hold documentary evidence for objective claims before publication, and the ASA will assess those claims by reference to the impression they are likely to create on consumers. That means phrases such as “clinically proven”, “scientifically proven”, “proven results” or time-bound performance claims can create real risk if the evidence does not fully support the message consumers are likely to take away. Recent commentary on similar ASA rulings this year points in the same direction: subjective consumer perception data and imperfect testing are unlikely to be enough for bold, scientific-sounding claims.